

# **CURRICULUM VITAE**

**David L. Cooke, MD**

## **PRACTICE LOCATIONS**

Great Lakes Eye Care 2848 Niles Road St. Joseph, MI 49085 (269) 428-3300 Fax: (269) 428-5005	Great Lakes Eye Care 120 Longmeadow Village Dr. Niles, MI 49120 (269) 684-6400 Fax: (269) 684-5103	Great Lakes Eye Care 412 Phoenix Street South Haven, MI 49090 (269) 637-3101 Fax: (269) 637-4000
--	--	--

---

## **TRAINING**

### **Mayo Clinic:**

Rochester, MN      Residency in Ophthalmology      1984-1987

### **Saint Joseph Hospital**

Ann Arbor, MI      Internship      1982-1983

### **University of Michigan**

Ann Arbor, MI      Accelerated Pre-Med/Medical Inteflex Program  
M.D. Degree      1982  
B.A. Degree with distinction      1981

---

## **CERTIFICATION**

Board Certified in Ophthalmology      1989

---

## **LICENSURE**

Michigan 1983-present      License # 4301046231  
Indiana 1984-present      License # 01033191A

---

## **PROFESSIONAL MEMBERSHIPS**

American Medical Association  
American Academy of Ophthalmology  
Michigan State Medical Society  
Berrien County Medical Society  
Christian Medical and Dental Society  
Vision Outreach International-Member of the Board  
American Society of Cataract and Refractive Surgeons  
European Society of Cataract and Refractive Surgeons

---

## **PROFESSIONAL PRIVILEGES**

### **Lakeland Community Hospital**

Niles, Michigan      1995 to present

### **Lakeland Regional Medical Center**, including Center for Outpatient Services

Saint Joseph, Michigan      1987 to present

---

## **PRESENTATIONS**

**Cooke DL.** SpikeFinder: Our version of the LENSTAR software. IOL Power Club, St. Pete Beach, FL, October 2018.

**Cooke DL.** Sum-of-Segments AL Improves Formulas Originally Designed With Ultrasound. IOL Power Club, St. Pete Beach, FL, October 2018.

**Cooke DL.** K6 - Our Version of the General Vergence Formula. IOL Power Club, St. Pete Beach, FL, October 2018.

**Cooke DL.** Comparison of Lenstar and ARGOS. IOL Power Club, St. Pete Beach, FL, October 2018.

**Cooke DL.** How to choose an IOL. Coursera for University of Michigan, Ann Arbor, MI, October 2013.

**Cooke DL.** Adding posterior corneal astigmatism to toric IOL calculations. ASCRS (American Society of Cataract and Refractive Surgery) Symposium, San Francisco, CA, April 2013.

Cooke MD, **Cooke DL.** Effect of IOL Style on Rate of Retinal Tear or Detachment After Phacoemulsification. ASCRS (American Society of Cataract and Refractive Surgery) Symposium, San Francisco, CA, April 2013.

**Cooke DL,** Sheard R, Smith GT. Improving the Prediction Accuracy of SRK/T Formula: T2 Formula. ASCRS (American Society of Cataract and Refractive Surgery) Symposium, San Diego, CA, March 2011. **Award:** Best Paper of Session; I-F Intraocular Surgery: Power Calculations.

Smith GT, Sheard R, **Cooke DL.** Using First-Eye Outcome to Improve Biometric Outcome of Second-Eye Post-Phacoemulsification. ASCRS (American Society of Cataract and Refractive Surgery) Symposium, San Diego, CA, March 2011.

Rapoza P, **Cooke DL,** Beahm D, Stewart R, Walters T, Grillone L. Investigative Study of Bioequivalence of Prednisolone Acetate 1% and Tobramycin 0.3% Compared with Prednisolone Acetate 1%. ASCRS (American Society of Cataract and Refractive Surgery) Symposium, San Diego, CA, April 2007.

## PUBLICATIONS

Stonecipher KG, Holladay JT, **Cooke DL,** Fisher BL, Devgan U. Previous eight-incision radial keratotomy: Trying to fix a refractive surprise after cataract surgery. *Cataract & Refractive Surgery Today Europe.* 2018;8:18-23.

Stonecipher KG, Holladay JT, **Cooke DL,** Fisher BL, Devgan U. Previous eight-incision radial keratotomy: Trying to fix a refractive surprise after cataract surgery. *Cataract & Refractive Surgery Today.* 2018;8:35-42.

Gökce SE, De Oca IM, **Cooke DL,** Wang L, Koch DD, Al-Mohtaseb Z. Accuracy of 8 intraocular lens calculation formulas in relation to anterior chamber depth in patients with normal axial lengths. *Journal of Cataract & Refractive Surgery.* 2018;44:362-368.

**Cooke DL.** Cooke TL. Effect of Altering Lens Constants. *Journal of Cataract & Refractive Surgery.* 2017;43:853.

**Cooke DL.** Unexpectedly low power formula lens constants. *Journal of Cataract & Refractive Surgery.* 2017;43:433.

**Cooke DL,** Cooke TL. Comparison of 9 intraocular lens power calculation formulas. *Journal of Cataract & Refractive Surgery.* 2016;42:1157-1164.

**Cooke DL,** Cooke TL. Prediction accuracy of preinstalled formulas on 2 optical biometers. *Journal of Cataract & Refractive Surgery.* 2016;42:358-362.

**Cooke DL.** Dealing with negative dysphotopsia: If the symptom persists, laser and then surgical interventions can be effective. *Cataract & Refractive Surgery Today Europe.* 2015; 10:44-46.

**Cooke DL.** Predictability of intraocular lens power calculation formulae in infantile eyes with unilateral congenital cataract: Results from the infant aphakia treatment study. *American Journal of Ophthalmology.* 2014;157:1332.

Sanders DR, Sarver EJ, **Cooke DL.** Accuracy and precision of a new system for measuring toric intraocular lens axis rotation. *Journal of Cataract & Refractive Surgery.* 2013;39:1190-1195.

**Cooke DL,** Kasko S, Platt LO. Resolution of negative dysphotopsia after laser anterior capsulotomy. *Journal of Cataract & Refractive Surgery.* 2013;39:1107-1109.

Hill W, Osher R, **Cooke DL,** Solomon K, et al., Simulation of toric intraocular lens results: Manual keratometry versus dual-zone automated keratometry from an integrated biometer. *Journal of Cataract & Refractive Surgery.* 2011;37:2181-2187.

Sheard R, Smith G, **Cooke DL.** Reply: Comments on study of SKR/T versus T2 formula, Comments on: Improving the prediction accuracy of the SRK/T formula: The T2 formula and What Constitutes "Clinically Significant" Improvement in Implant Power Calculation Accuracy? *Journal of Cataract & Refractive Surgery.* 2011;37:796-798.

Lewis RA, Gross RL, Sall KN, Schiffman RM, et al, for the Ganfort Investigators Group II, including **Cooke DL.** The safety and efficacy of bimatoprost/timolol fixed combination: A 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. *Journal of Glaucoma.* 2010;19:424-426.

Sheard RM, Smith GT, **Cooke DL.** Improving the prediction accuracy of the SRK/T formula: The T2 formula. *Journal of Cataract & Refractive Surgery.* 2010;36:1829-1834.

**Cooke DL.** Reply: Optical phenomena causing negative dysphotopsia. *Journal of Cataract & Refractive Surgery.* 2010; 36:1620-1621.

**Cooke DL.** Reply: Differentiating transient and permanent negative dysphotopsia. *Journal of Cataract & Refractive Surgery.* 2010;36:1619-1620.

**Cooke DL.** Negative dysphotopsia after temporal corneal incisions. *Journal of Cataract & Refractive Surgery.* 2010;36:671-672.

Katz LJ, Cohen JS, Batoosingh AL, Felix C, et al., including principal investigator **Cooke DL**. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. *American Journal of Ophthalmology*. 2010;149:661-671.

Korenfeld MS, Silverstein SM, **Cooke DL**, Vogel R, et al., and the Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. *Journal of Cataract & Refractive Surgery*. 2009;35:26-34.

**Cooke DL**. Correlation between preoperative refraction and other variables. *Journal of Cataract & Refractive Surgery*. 2008;34:1618-1619.

Williams RD, Cohen JS, Gross RL, Liu CC, et al., for the Bimatoprost Study Group for Principal Investigators, including **Cooke DL**. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: Year 4. *British Journal of Ophthalmology*. 2008;92:1387-1392.

Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, et al., for the Ganfort Investigators Group II, including **Cooke DL**. Bimatoprost/timolol fixed combination: A 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. *Journal of Glaucoma*. 2008;17:211-216.

Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, et al., for the Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group, including **Cooke DL**. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. *Ophthalmology*. 2007; 114:1653-1662e1.

Hommer A, Boone WB, Branch JD, Brigatti L, et al. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. *European Journal of Ophthalmology*. 2007; 17:53-62.

Shin DH, Feldman RM, Sheu WP, and Fixed Combination Latanoprost/Timolol Study Group, including **Cooke DL**. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. *Ophthalmology*. 2004;111:276-282.

DuBiner H, **Cooke DL**, Stewart W, VanDenburgh A, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. *Survey of Ophthalmology*. 2001;45 (Suppl 4):S353-S360.

Sherwood M, Brandt J, and Bimatoprost Study Groups 1 and 2, including **Cooke DL**. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. *Survey of Ophthalmology*. 2001;45(Suppl 4):S361-S368.

Schuman JS, for the Brimonidine Study Groups 1 and 2, including **Cooke DL**. Effects of systemic  $\beta$ -blocker therapy on the efficacy and safety of topical brimonidine and timolol. *Ophthalmology*. 2000;107:1171-1177.

Dirks M, DuBiner H, **Cooke DL**, Stewart W, et. al. Efficacy and safety of the ocular hypotensive lipid AGN-192024 in patients with elevated IOP: A 30-day comparison with latanoprost. *Investigative Ophthalmology and Visual Science*. 2000;15;41(4):S514 ABS2737 B983.

Konowal A, Morrison JC, Brown SV, **Cooke DL**, et. al. Irreversible corneal decompensation in patients treated with topical dorzolamide. *American Journal of Ophthalmology*. 1999;127:403-406.

Katz, LJ and the Brimonidine Study Group, including **Cooke DL**. Brimonidine tartrate 0.2% twice daily vs. timolol 0.5% twice daily: 1-year results in glaucoma patients. *American Journal of Ophthalmology*. 1999;127:20-26.

Novak, G and the Loteprednol Etabonate Postoperative Inflammation Study Group 2, including **Cooke DL**. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. *Ophthalmology*. 1998;105:1780-1786.

Atlas W, Baum K, **Cooke DL**, DuBiner H, et.al. The clinical success rate and quality of life assessment of brimonidine tartrate 0.2% compared with timolol .05% administered twice daily, in patients with previously untreated open angle glaucoma or ocular hypertension. *Drug Information Journal*. 1997;31(4):1432.

## AWARDS

Recognized Reviewer Status from *Journal of Cataract & Refractive Surgery*, February 2016.

Great Lakes Eye Care awarded Trial Runners "Site of the Month," August 2016.

---

## RESEARCH

Principal Investigator in the attached protocols.

---

## PERSONAL INFORMATION

<b>Email:</b>	davidcooke@gmail.com	
<b>Date of Birth:</b>	March 9, 1958	Chicago, Illinois
<b>Education:</b>		
Berrien Springs High School	1972-1976	
Berrien Springs, Michigan		
<b>Spouse's Name:</b>	Jeannette Cooke	
<b>Children:</b>	Matthew, Timothy, Joshua	

---

Signed \_\_\_\_\_ Date \_\_\_\_\_  
David L. Cooke, M.D.

David L. Cooke 5

Attachments:

DC Rev 1/12